Medicare Policy Shouldn’t Be Made in the Shadows
Medicare policy should be transparent and include appropriate notice and stakeholder input. And when a…
Medicare Policy Shouldn’t Be Made in the Shadows
Medicare policy should be transparent and include appropriate notice and stakeholder input. And when a contractor gets it wrong, there should be a clear and rapid way to stop the harm to patients, their relationship with their doctor and the doctor’s practice. The post Medicare Policy Shouldn’t Be Made in the Shadows appeared first on…
What Corporate Venture Funds Get Wrong about Strategic Value
Corporate venture funds often chase financial returns while ignoring strategic value. Here’s what it takes to turn healthcare portfolio investments into lasting business impact. The post What Corporate Venture Funds Get Wrong about Strategic Value appeared first on MedCity News.
People Say These Peptides Hurt Them. Their Stories Are Muffled in MAHA’s Push for Medical Freedom.
After the third day of squirting an experimental drug up his nose, Dylan Meetze felt horrible. “It was like I was underwater, like it took the most to do anything,” he said. Meetze stopped taking the drug but endured fatigue and anxiety for months afterward, and his eyes and muscles twitched, he said. He had…
Fears About Kids’ Online Safety Unite Democrats and Republicans
The U.S. Senate candidates in Texas could hardly be more different: James Talarico, a former seminarian turned Democratic state lawmaker who speaks in calm cadences about love and empathy, and Ken Paxton, the pugnacious Republican state attorney general who speaks about a refusal to compromise. They share an enemy, though. They dislike social media’s effects…
The Sometimes-Awkward Art of Asking for a Second Opinion
When Carol Daniel, a veteran broadcast journalist who lives near St. Louis, was diagnosed with thyroid cancer in 2022, her husband encouraged her to seek a second opinion. She was worried that consulting another doctor might seem like a betrayal. Daniel said she wondered: “Am I cheating on him? Am I going behind his back?…
AI in Health Care: Who Gets Left Behind?
Health care’s AI future is being built right now. The open question is “for whom?” Dr. Uché Blackstock — emergency physician, former associate professor at NYU School of Medicine, founder and CEO of Advancing Health Equity, and author of The New York Times bestseller “Legacy: A Black Physician Reckons with Racism in Medicine” — joins…
Healthix HIE Plays Role in N.Y.’s Efforts to Meet Medicaid Work Rule Requirements
HIE is creating dashboards to identify who’s most at risk of losing coverage and who might fall into the exemption categories
Employers that exclude GLP-1s point staff to a website and a pretax account
By JOHN SAMARAS Most employers still won’t cover GLP-1s for weight loss, and some of them now tell the employee where to buy them without the plan. The International Foundation of Employee Benefit Plans’ 2026 survey, published in July, found that 60 percent of employers cover the drugs for diabetes only and 36 percent for…
CMS, GAO Reports Offer Early Look at Rural Health Funding and Oversight
New reports examine state spending, progress and oversight
Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug
Asahi Kasei’s Hovilpri is now approved for treating lesions caused by herpes simplex virus infection. This daily pill came from the $919 million acquisition of AiCuris Anti-Infective Cures. The post Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug appeared first on MedCity News.
